{
    "nctId": "NCT01894711",
    "briefTitle": "Real World Efficiency of Trastuzumab in Early Breast Cancer",
    "officialTitle": "Real-world Use and (Cost)-Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2684,
    "primaryOutcomeMeasure": "Effectiveness of the use of trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) positive tumor",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients diagnosed with invasive stage I-III breast cancer in the years 2005, 2006 and 2007 in the participating 5 hospitals.\n\nExclusion Criteria:\n\n* Distant metastasis at the time of the primary diagnosis",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}